Stockreport

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? [Globe and Mail, The (Toronto, Canada)]

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF The sale represented 4.9% of Mr. Santos da Silva's direct holdings, reducing his directly held position to 2,924,893 shares as of April 13, 2026. The transaction was [Read more]